Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 - 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...

Automatic Swimming Pool Monitoring System Market Revenue to Cross USD 7.5 billion by 2031, Expanding at a CAGR of 4.9% - Exclusive Report by Transparency Market Research Wilmington, Delaware, United States, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global automatic swimming pool monitoring system market is projected to flourish at a...